Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
April 2014, Vol 5, No 3
April 2014, Vol 5, No 3
Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management
By
Wayne Kuznar
NCCN 2014 Conference
,
NCCN Guidelines
,
Policies & Guidelines
April 2014, Vol 5, No 3
Hollywood, FL—The updated guidelines from the National Comprehensive Cancer Network (NCCN) for the management of non-Hodgkin lymphoma (NHL) includes new strategies in the management of diffuse large B-cell lymphoma (DLBCL) and new guidelines for T-cell lymphoproliferative disorders.
Read Article
Harnessing CMS’s Meaningful Use Criteria to Transform Cancer Care with EMRs
By
Rosemary Frei, MSc
Cancer Care
,
Oncology
,
Personalized Medicine
April 2014, Vol 5, No 3
Washington, DC—A new framework for transforming cancer care by harnessing the meaningful use criteria of the Centers for Medicare & Medicaid Services (CMS) was proposed by a team of researchers at the 2013 American Medical Informatics Association meeting.
Read Article
High Rate of Overridden Drug Contraindication Alerts for Patients with Cancer
By
Rosemary Frei, MSc
Oncology
April 2014, Vol 5, No 3
Washington, DC—Patients with cancer are often prescribed medications for the treatment of comorbid conditions, and some of those medications may have harmful drug interactions with the therapies used to treat their cancer. Computerized alert systems are now being used to inform providers or support personnel on such contraindications.
Read Article
In the Real World, Bevacizumab Improves Survival in Patients with Metastatic Colorectal Cancer
By
Wayne Kuznar
Colorectal Cancer
April 2014, Vol 5, No 3
San Francisco, CA—In routine patient care, adding bevacizumab (Avastin) to standard FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan) improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC), according to data presented at the 2014 Gastrointestinal Cancers Symposium.
Read Article
Personalized Cancer Care: Combination Therapies May Be Key to Hitting Tumor Heterogeneity
By
Wayne Kuznar
Personalized Medicine
April 2014, Vol 5, No 3
Boston, MA—Combinations of targeted therapies will be key to overcoming resistance that occurs in tumor cells and leads to eventual failure of a single targeted agent, said Alex Adjei, MD, PhD, the Katherine Anne Gioia Chair in Cancer Medicine, Roswell Park Cancer Institute, Buffalo, NY, at the Second Global Biomarkers Consortium annual conference.
Read Article
New Molecular Test to Monitor Breast Cancer Recurrence by Sequencing Circulating Tumor Cells
By
Wayne Kuznar
Personalized Medicine
April 2014, Vol 5, No 3
A genomic test to sequence the circulating tumor cells (CTCs) from whole blood, ClearID Breast Cancer from Cynvenio Biosystems, is now available commercially to molecularly monitor for breast cancer recurrence. The test uses a standard blood draw from which DNA from tumor cells is isolated and interrogated using next-generation–sequencing tools to determine the presence of cancer-associated DNA mutations.
Read Article
Oncotype DX May Not Be Necessary to Predict Recurrence in Low-Grade Breast Cancer
By
Rosemary Frei, MSc
Personalized Medicine
April 2014, Vol 5, No 3
San Diego, CA—Results of a new small study have shown that histology without the use of Onco
type
DX Breast Cancer assay accurately predicts the risk for recurrence in low-grade breast carcinoma. Although Oncotype DX is useful in predicting recurrence in high-grade breast cancer, this study suggests that low-grade tumors may be adequately assessed for recurrence by histology only.
Read Article
Imaging Choice May Influence Brachytherapy Outcomes
By
Charles Bankhead
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
San Francisco, CA—Magnetic resonance imaging (MRI)-guided brachytherapy led to significantly less urinary dysfunction in men being treated for localized prostate cancer compared with ultrasound-guided techniques, according to a long-term prospective cohort study reported at the 2014 Genitourinary Cancers Symposium.
Read Article
Phi Index Can Select Patients with Prostate Cancer for Active Surveillance
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
April 2014, Vol 5, No 3
San Francisco, CA—A new tool called the Prostate Health Index (phi) can identify which patients with favorable-risk prostate cancer can safely be managed with active surveillance and which patients will probably require treatment. The
phi
index is relatively low tech and is calculated using 3 serum measurements: prostate-specific antigen (PSA), free/total PSA, and a measurement called [-2]proPSA.
Read Article
Ramucirumab Improves Survival as Second-Line Therapy in Patients with Advanced Gastric Cancer
By
Wayne Kuznar
Gastric Cancer
April 2014, Vol 5, No 3
San Francisco, CA—Phase 3 data from a global clinical trial have demonstrated an improvement in overall survival (OS) when the investigational angiogenesis inhibitor ramucirumab is added to chemotherapy as second-line therapy in patients with advanced gastric cancer.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma